US Cullinan Oncology, based in Cambridge, MA, and German MAB Discovery (MABD) announced the initiation of a collaboration to develop novel antibody therapeutics based on MABD's discovery platform.
"We are excited to enter into this collaboration as the MABD development engine provides us with access to highly differentiated monoclonal antibodies," said Patrick Baeuerle, Cullinan's CSO Biologics. "Our first program is a novel agonistic antibody that has the potential to be a pillar of future immuno-oncology and standard treatments. We look forward to working with Stephan Fischer and the MABD team to execute the development plan and progress the asset into the clinic."
Under the terms of the agreement, MABD has the potential to receive cash payments upon the achievement of various milestones in addition to an upfront equity interest in Cullinan Wittelsbach, a subsidiary of Cullinan Oncology formed to fund and manage the development of the asset.
Stephan Fischer, CEO of MAB Discovery, stated: "We are delighted to partner with Patrick and the Cullinan team, and look forward to understanding how the unique attributes of our rabbit-based platform translate into highly differentiated antibodies that have the potential to significantly advance patient outcomes."
